This page contains exclusive content for the member of the following sections: TTS, CTS
Oral Communications 3
8.3 - Circulating miR-375 levels after islet transplantation in humans: a biomarker of ongoing beta cell injury
Presenter: Lorenzo, Piemonti, Milan, Italy Authors: Lorenzo Piemonti1,2, Miguel Correa-Tapia 1,2, Vito Lampasona1,2, Jorge Ferrer1,2
Circulating miR-375 levels after islet transplantation in humans: a biomarker of ongoing beta cell injury
Lorenzo Piemonti1,2, Miguel Correa-Tapia 1,2, Vito Lampasona1,2, Jorge Ferrer1,2
1Diabetes Research Institute (OSR-DRI), San Raffaele Scientific Institute, Milan, Italy; 2Genomic Programming of Beta-cells Laboratory, Institut d'Investigacions August Pi i Sunyer (IDIBAPS); CIBER de Diabetes y Enfermedades MetabÃ³licas Asociadas (CIBERDEM), Barcellona, Spain
Background.Circulating level of the pancreatic islet enriched miR-375 was recently described as a biomarker of beta cell death1. We tested if circulating levels of miR-375 reflect beta cell destruction in patients with type 1 diabetes who received human pancreatic islets.
Methods/Materials.A total of 22 human islet infusion were studied under different immunosuppression regimen: alphaCD25/Rapa/FK506 (n=6), ATG/MMF/FK506 (n=13) and none (auto trasplantation; n=3). MiR-375 circulating levels were evaluated by quantitative PCR (TaqMan Assay and/or droplet digital PCR).
Results.Human pancreatic islet expressed high level of miR-375. After transplantation serum miR-375 increased up to 200-fold during the first 12 hours, and then dropped to moderately elevated levels after 24 hours. This change was present both in allogenic and autologous islet transplantation. Circulating miR-375 levels were again increased at 96 hours post islet-infusion. This second peak was preceded by the rise of C-reactive protein and cross-linked fibrin degradation products, and it was followed by the rise of cell damage markers (AST, ALT and LDH). We compared miR-375 levels in patients with and without CXCR1/2 inhibitor therapy, a treatment that preserves <beta> cell mass by dampening inflammatory damage (Citro, A. et al J. Clin. Invest. 2012;122:3647). All patients showed similarly increased circulating miR-375 levels during the 24 hr period that followed the infusion. However, the elevations of miR-375 levels that were observed at 48 and 96 hours post-islet infusion in control patients were not observed in patients treated with CXCR1/2inihibitors (p=0.048 and 0.024, respectively). Concordantly, CXCR1/2 inhibitor therapy preserved increased beta cell function during the time.
Conclusion.The results suggest that circulating miR-375 levels is a useful non-invasive indicator of ongoing beta cell injury after islet transplantation.
1. Erener, S. et al. Endocrinology 2013; 154:603
You must be logged in to view recordings
By viewing the material on this site you understand and
The opinions and statements expressed on this site reflect the
views of the author or authors and do not necessarily reflect those of
The Transplantation Society and/or its Sections.
The hosting of material on The Transplantation Society site does
not signify endorsement of this material by The Transplantation Society
and/or its Sections.
The material is solely for educational purposes for qualified
health care professionals.
The Transplantation Society and/or its Sections are not liable for
any decision made or action taken based on the information contained in
the material on this site.
The information cannot be used as a substitute for professional
The information does not represent a standard of care.
No physician-patient relationship is being established.
The Transplantation Society
505 Boulevard René-Lévesque Ouest
Montréal, QC, H2Z 1Y7